Prostate cancer (PCa) shows a broad spectrum of biological and clinical behavior, which represents the epiphenomenon of an extreme genetic heterogeneity. Recent genomic profiling studies have deeply improved the knowledge of the genomic landscape of localized and metastatic PCa. The AR and PI3K/Akt/mTOR signaling pathways are the two most frequently altered, representing therefore interestingly targets for therapy. Moreover, somatic or germline aberrations of DNA repair genes (DRGs) have been observed at high frequency, supporting the potential role of platinum derivatives and PARP inhibitors as effective therapeutic strategies. In the future, the identification of driver mutations present at a specific stage of the disease, the classification PCa based on specific molecular alterations, and the selection of the most appropriate therapy based on biomarkers predictors of response represent the foundations for an increasingly more accurate personalized medicine.

Ciccarese, C., Massari, F., Iacovelli, R., Fiorentino, M., Montironi, R., Di Nunno, V., Giunchi, F., Brunelli, M., Tortora, G., Prostate cancer heterogeneity: Discovering novel molecular targets for therapy, <<CANCER TREATMENT REVIEWS>>, 2017; 54 (marzo): 68-73. [doi:10.1016/j.ctrv.2017.02.001] [http://hdl.handle.net/10807/134260]

Prostate cancer heterogeneity: Discovering novel molecular targets for therapy

Ciccarese, Chiara;Iacovelli, Roberto;Tortora, Giampaolo
2017

Abstract

Prostate cancer (PCa) shows a broad spectrum of biological and clinical behavior, which represents the epiphenomenon of an extreme genetic heterogeneity. Recent genomic profiling studies have deeply improved the knowledge of the genomic landscape of localized and metastatic PCa. The AR and PI3K/Akt/mTOR signaling pathways are the two most frequently altered, representing therefore interestingly targets for therapy. Moreover, somatic or germline aberrations of DNA repair genes (DRGs) have been observed at high frequency, supporting the potential role of platinum derivatives and PARP inhibitors as effective therapeutic strategies. In the future, the identification of driver mutations present at a specific stage of the disease, the classification PCa based on specific molecular alterations, and the selection of the most appropriate therapy based on biomarkers predictors of response represent the foundations for an increasingly more accurate personalized medicine.
2017
Inglese
Ciccarese, C., Massari, F., Iacovelli, R., Fiorentino, M., Montironi, R., Di Nunno, V., Giunchi, F., Brunelli, M., Tortora, G., Prostate cancer heterogeneity: Discovering novel molecular targets for therapy, <<CANCER TREATMENT REVIEWS>>, 2017; 54 (marzo): 68-73. [doi:10.1016/j.ctrv.2017.02.001] [http://hdl.handle.net/10807/134260]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/134260
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 59
social impact